<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103724</url>
  </required_header>
  <id_info>
    <org_study_id>INT 178-15</org_study_id>
    <nct_id>NCT03103724</nct_id>
  </id_info>
  <brief_title>A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.</brief_title>
  <acronym>EXCALIBUR</acronym>
  <official_title>A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, single arm, phase II multicentre study designed to determine the clinical
      benefit, as measured by 3-months disease control rate (DCR) provided by enzalutamide in
      metastatic Castration Resistant Prostate Cancer patients with at least one visceral site
      involvement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">March 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the clinical benefit, as measured by 3 months disease control rate (DCR) provided by enzalutamide in mCRPC patients with visceral disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the treatment per NCI-CTCA v. 4.0</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the safety of the treatment according to NCI-CTCA v. 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate quality of life as assessed by EQ-5D-5L e FACT-P questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate pain as assessed by BPI-SF questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Carcinoma Prostate</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xtandi</intervention_name>
    <description>Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily</description>
    <arm_group_label>Enzalutamide</arm_group_label>
    <other_name>Enzalutamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18

          2. ECOG PS 0-1-2

          3. Biopsy (primary tumour or metastases) confirming the diagnosis of prostate
             adenocarcinoma

          4. Documented measurable metastatic visceral disease (according to RECIST 1.1 criteria)
             considering metastases in lung or liver or extraregional lymphnodes

          5. Written informed consent

          6. Platelets &gt; or = 100 x109/L; haemoglobin &gt; or = 9 g/dl; neutrophils &gt; or 1.5 x 109/L

          7. Bilirubin &lt; or = 2 mg/dl, AST and ALT &lt; or = 2.5 times the UNL or &lt; or = 5 times UNL
             for pts with liver metastases; serum albumin &gt; or = the LNL

          8. Patients of childbearing age should use contraceptive methods

          9. Life expectancy &gt; 3 months

         10. Able to swallow the study drug and comply with study requirements;

         11. Willing and able to give informed consent.

         12. Ongoing androgen deprivation therapy with a GnRH analogue or orchiectomy (i.e.,
             surgical or medical castration);

         13. Patients may have received previous therapy including chemotherapy (docetaxel) last
             cycle must be received 3 weeks before start of experimental treatment. Hormonal
             treatment containing bicalutamide must be interrupted 2 weeks before start of study
             therapy

         14. Previous radiotherapy (prostate and/or bone) is accepted but must be interrupted 3
             weeks before start of experimental treatment.

         15. Serum testosterone level &lt; 1.7 nmol/L (50 ng/dL) at the Screening visit

         16. Progressive disease by PSA or imaging in the setting of medical or surgical
             castration. Disease progression for study entry is defined as one or more of the
             following three criteria (according with PCWG2):

               -  PSA progression defined by a minimum of three rising PSA levels with an interval
                  of ≥ 1 week between each determination. The PSA value at the Screening visit
                  should be ≥ 2 g/L (2 ng/ml); if the third PSA value is less than second PSA, a
                  fourth PSA must be repeated and if it the value is higher than second must be
                  considered as disease

               -  Soft tissue/visceral disease progression defined by RECIST 1.1;

               -  Bone disease progression defined by two or more new lesions on bone scan.

        Exclusion Criteria:

          1. Severe, concurrent disease, infection, or co-morbidity that, in the judgment of the
             investigator, would make the patient inappropriate for enrollment;

          2. Metastases in the brain or active epidural disease;

          3. History of another malignancy within the previous 5 years other than curatively
             treated non-melanomatous skin cancer;

          4. History of seizure, including any febrile seizure, loss of consciousness, or transient
             ischemia attack within 12 months of enrollment (Day 1 visit), or any condition that
             may pre-dispose to seizure (e.g., prior stroke, head trauma with loss of consciousness
             requiring hospitalization);

          5. Clinically significant cardiovascular disease including: Myocardial infarction within
             6 months; Uncontrolled angina within 3 months; Congestive heart failure New York Heart
             Association (NYHA) class 3 or 4, or patients with history of congestive heart failure
             NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated
             acquisition scan (MUGA) performed within 3 months results in a left ventricular
             ejection fraction that is ≥ 45%;

          6. Diagnosed or suspected congenital long QT syndrome;

          7. History of clinically significant ventricular arrhythmias (e.g., ventricular
             tachycardia, ventricular fibrillation, torsades de pointes);

          8. Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer
             within last 3 months);

          9. Major surgery within 4 weeks prior to enrollment (Day 1 visit);

         10. Prior treatment with abiraterone acetate;

         11. Participation in a clinical trial about an experimental anti-androgen agent (eg.
             ARN-509, ODM-201, VT-464, except for placebo arm);

         12. Treatment (concomitant or in the previous 2 weeks) with anti-androgens (eg.
             Bicalutamide, nilutamide, flutamide) or 5-a reductase inhibitors (eg. finasteride,
             dutasteride).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Verzoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale Tumori Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Verzoni, MD</last_name>
    <phone>+390223904449</phone>
    <email>Elena.verzoni@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosanna Montone, Dr.ssa</last_name>
    <phone>+390223903817</phone>
    <email>Rosanna.montone@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Elena Verzoni</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Verzoni, MD</last_name>
      <phone>+390223904449</phone>
      <email>Elena.verzoni@istitutotumori.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Rosanna Montone, Dr.ssa</last_name>
      <phone>+390223903817</phone>
      <email>Rosanna.montone@istitutotumori.mi.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Astellas Pharma Ltd. Xtandi (enzalutamide) 40mg soft capsules. Summary of Product Characteristics. 26 June 2013.</citation>
  </reference>
  <results_reference>
    <citation>Ahmed M, Li LC. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol. 2013 Apr;20(4):362-71. doi: 10.1111/iju.12005. Epub 2012 Nov 19. Review.</citation>
    <PMID>23163774</PMID>
  </results_reference>
  <results_reference>
    <citation>Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.</citation>
    <PMID>25184630</PMID>
  </results_reference>
  <results_reference>
    <citation>Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O; Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008 Jun;179(6):2181-5; discussion 2185-6. doi: 10.1016/j.juro.2008.01.099. Epub 2008 Apr 18.</citation>
    <PMID>18423743</PMID>
  </results_reference>
  <results_reference>
    <citation>Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Oct 30;371(18):1755-6. doi: 10.1056/NEJMc1410239.</citation>
    <PMID>25354111</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010 Mar;46(4):765-81. doi: 10.1016/j.ejca.2009.12.014. Epub 2010 Jan 29.</citation>
    <PMID>20116997</PMID>
  </results_reference>
  <results_reference>
    <citation>Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2014 Jun;65(6):1198-204. doi: 10.1016/j.eururo.2013.07.022. Epub 2013 Jul 25. Review.</citation>
    <PMID>23910941</PMID>
  </results_reference>
  <results_reference>
    <citation>Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.</citation>
    <PMID>24321502</PMID>
  </results_reference>
  <results_reference>
    <citation>Horwich A, Parker C, de Reijke T, Kataja V; ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi106-14. doi: 10.1093/annonc/mdt208. Epub 2013 Jun 27.</citation>
    <PMID>23813930</PMID>
  </results_reference>
  <results_reference>
    <citation>Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 Feb;167(2 Pt 2):948-51; discussion 952.</citation>
    <PMID>11905923</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol. 2013 Oct;10(10):571-87. doi: 10.1038/nrclinonc.2013.158. Epub 2013 Sep 3. Review.</citation>
    <PMID>23999218</PMID>
  </results_reference>
  <results_reference>
    <citation>Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM; European Treatment Practices Group. Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013;18(5):558-67. doi: 10.1634/theoncologist.2012-0478. Epub 2013 May 13. Review. Erratum in: Oncologist. 2013;18(8):971. Oncologist. 2013;18(6):775.</citation>
    <PMID>23671006</PMID>
  </results_reference>
  <results_reference>
    <citation>Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.</citation>
    <PMID>7165009</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.</citation>
    <PMID>23228172</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011 Sep 20;29(27):3651-8. doi: 10.1200/JCO.2011.35.2005. Epub 2011 Aug 22. Review.</citation>
    <PMID>21859989</PMID>
  </results_reference>
  <results_reference>
    <citation>Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.</citation>
    <PMID>20398925</PMID>
  </results_reference>
  <results_reference>
    <citation>Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.</citation>
    <PMID>22894553</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

